Clinical Trials Directory

Trials / Completed

CompletedNCT04451811

A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

A Pharmacokinetic Dose Proportionality Study of OPL-002 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Oppilan Pharma Ltd · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This is a single center, randomized, open-label, three-way crossover, single dose, pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGOPL-002Spray dried dispersion and tablet formulation

Timeline

Start date
2020-09-07
Primary completion
2021-02-24
Completion
2021-02-24
First posted
2020-06-30
Last updated
2021-05-28

Locations

1 site across 1 country: United Kingdom

Regulatory

Source: ClinicalTrials.gov record NCT04451811. Inclusion in this directory is not an endorsement.